Multi-omics endotype of preterm infants with bronchopulmonary dysplasia and

pulmonary hypertension

Roopa Siddaiah¹, Christiana Oii-Mmuo¹, Vincent Aluquin¹, Yuka Imamura Kawasawa²,

Ann Donnelly³, Dustin Rousselle⁴, Nathalie Fuentes¹, Eric D. Austin⁵, and Patricia

Silveyra^{1,4}

¹ Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA

² Department of Pharmacology, Penn State Health Children's Hospital, Hershey, PA

³ Department of Respiratory Therapy, Penn State Health Children's Hospital, Hershey,

PA

⁴ Department of Environmental and Occupational Health, Indiana University School of

Public Health, Bloomington, IN

⁵ Department of Pediatrics, Vanderbilt University, Vanderbilt, TN

Corresponding author:

Roopa Siddaiah

500 University Drive, Hershey PA

T: 717-531-5412; F: 717-531-0761

Email: rsiddaiah@pennstatehealth.psu.edu

Author contributions: RS: Conception, research design, sample collection, data

interpretation, manuscript preparation and final approval of manuscript. CO, VA, YIK, AD,

DR, NF, EA: Research design, sample collection, data interpretation, critical revision of

manuscript. PS: Conception, research design, data analysis and data interpretation,

sample processing, manuscript preparation.

Funding source: Center for Research on Women and Newborn Health; Children's

Miracle Network, Department of Pediatrics Startup funding, Penn State Health Core

facility laboratory.

Short running title: Tracheal aspirate multi-omics in infants with sBPD

Subject Category: 14.3

Total word count of the body of the manuscript:

This article has an online data supplement, which is accessible from this issue's table of

content online at www.atsjournals.org

Abstract

Rationale: Pulmonary hypertension associated with bronchopulmonary dysplasia is a

severe complication of preterm birth resulting in high mortality of up to 50% within the first

2 years of life. There is a direct relationship between bronchopulmonary dysplasia

severity and incidence of associated pulmonary hypertension. However, it is challenging

to clinically characterize severe bronchopulmonary dysplasia with and without pulmonary

hypertension and there is need for better understanding of the two entities.

Objectives: To identify markers to help understand biological processes and endotype

characterization of infants with pulmonary hypertension associated with

bronchopulmonary dysplasia in tracheal aspirates.

Methods: We conducted multi-omic analysis of tracheal aspirates via miRNA PCR

arrays, RNA sequencing and mass spectrometry proteomics in preterm infants with

severe bronchopulmonary dysplasia with (n=21) and without (n=25) pulmonary

hypertension.

Results: Our study analysis revealed 12 miRNAs (hsa-miR-29a, has-miR-542-3p, has-

miR-624, has-miR-183, hsa-miR-501-3p, hsa-miR-101, hsa-miR-3131, hsa-miR-3683,

hsa-miR-3193, hsa-miR-3672, hsa-miR-3128, and hsa-miR-1287); 6 transcripts (IL6,

RPL35P5, HSD3B7, RNA5SP215, OR2A1-AS1, and RNVU1-19), and 5 proteins (CAPS,

AAT, KRT5, SFTPB, and LGALS3BP) with significant differential expression in preterm

infants with severe lung disease with pulmonary hypertension when compared to infants

with severe lung disease but no pulmonary hypertension. Pathway analysis of the

integrated multi-omic expression signatures revealed NFkB, VEGF, SERPINA1, IL6 and

ERK12 as target molecules for miRNAs, and angiogenesis and hyperoxia stress as

recurrent pathways of individual markers.

Conclusion: Our multi-omic analysis of tracheal aspirates revealed a comprehensive

thumbprint of miRNAs, mRNAs and proteins that could help endotype infants with severe

lung disease and pulmonary hypertension.

Keywords: Multi-omics, Bronchopulmonary dysplasia, Pulmonary hypertension,

2

Angiogenesis, Preterm infants, Tracheal aspirate

Introduction

With recent advances in neonatal care, there is improved survival of extremely premature babies with very low birth weight, although significant reductions in complications of bronchopulmonary dysplasia (BPD) remain lacking (1). The pathogenesis of BPD is multifactorial and clinical phenotypes highly variable. While halted alveolar and pulmonary vascular growth have been identified as key players in the pathophysiology of "new BPD", one of its more severe complications is pulmonary hypertension associated with BPD (BPD-PH) which carries significant high morbidity and mortality (2).

The true incidence of BPD-PH in preterm babies is unknown. While the prevalence of BPD-PH is roughly one-third of all BPD cases, it is much higher in severe BPD (17%-43%) (3-5). Strictly speaking, the diagnosis of BPD is made around 36 weeks of gestational age (6, 7), while BPD-PH presents in both infancy and young childhood. Development of BPD-PH leads to increased number of days in the neonatal intensive care (NICU), increased number of days on ventilatory support, and oxygen requirement (8). In addition, a large number of these babies also require tracheostomy and home ventilatory support for prolonged periods (9). Once infants are discharged home, they continue to have high mortality and morbidity with increased hospital readmissions in the first 2 years of life (10, 11). Multiple factors including prenatal and postnatal environmental stressors such as inflammation, ventilator associated lung injury, hypoxic and hyperoxic stress, and others have been implicated in the etiology of BPD-PH (5, 12).

BPD is defined and classified based on the therapeutic need for respiratory support at 36 weeks postmenstrual age (PMA) and its outcomes (6, 7, 13). The disease phenotype of severe BPD (sBPD) is variable, hence differentiating its endotype is challenging in the absence of validated biomarkers. For example, Wu et al. recently showed that greater than 60% of infants with sBPD had pulmonary vascular disease (14). There is also significant overlap in the underlying pathophysiology of both sBPD and BPD-PH. Due to the complex array of contributing factors, the prevention, clinical diagnosis, and effective management of BPD-PH are challenging. The development of lung alveoli is dependent on pulmonary vascular development, and any disruption of vascular growth and signaling leads to reduction in alveolar development (15, 16). Studies have also indicated that postnatal imbalance between pro- and antiangiogenic factors triggered by inflammation, and oxidative and hypoxic stressors also contribute to the development of BPD-PH (17-19). While maternal preeclampsia, chorioamnionitis and small for gestational age are identified as the predominant risk factors for developing BPD-PH (17, 20) and could potentially predict its development, these are also factors that have been associated with development of sBPD. This limits their potential to be used as specific markers for BPD-PH prediction, thus novel markers are needed.

Although there have been some indications of hypoxic stress injury and vascular growth factors playing a role in the development of BPD-PH, there is currently a critical gap in our knowledge of the specific molecular pathways and mechanisms involved. In the current study, we conducted a multi-omics (proteomics, miRNAs, transcriptomics) profiling of tracheal aspirates of infants with sBPD and BPD-PH in order to identify key

biomarkers resulting from convergence of multiple pathophysiological processes occurring in both conditions.

Methods

Subjects and samples: Once approved by the Penn State Health institutional review board (STUDY 00000482), infants born < 28 weeks of gestation were screened, and informed consent obtained from parents. We included infants with diagnosis of severe BPD type II (13) or grade 3 BPD based on 2019 NICHD/NRN classification (7). Infants with congenital anomalies, chromosomal syndromes, and cyanotic cardiac defects were excluded. BPD-PH was defined based on echocardiogram features of elevated right sided pressures including interventricular septal flattening, tricuspid regurgitation jet velocity and annular plane systolic excursion, and pulmonary artery acceleration time. Tracheal aspirate (TA) was collected from 46 infants on ventilator, by instilling 1ml of normal saline and suctioning of endotracheal secretions. Samples were immediately stored at -80°C. Relevant clinical information was obtained by chart review. Samples were grouped into sBPD (n=25) (infants on invasive mechanical ventilation at 36 weeks PMA and no signs of PH on echocardiogram) and BPD-PH (n=21) (infants on invasive mechanical ventilation at 36 weeks PMA with signs of PH on echocardiogram).

MiRNA profiling: miRNAs were extracted and analyzed from 500 μL of TAs and analyzed with a miRNA array as described previously (21). Datasets were uploaded to GEO: https://www.ncbi.nlm.nih.gov/geo/guery/acc.cgi?acc=GSE205138. The top differentially

expressed miRNAs were validated in a subset of samples (n=17), with commercial miRNA assays (GeneCopoeia) and hsa-miR-16-1-3p as normalization control (22). Differential expression was calculated using the $2-\Delta\Delta$ CT method (23), and significant differences determined by Student's t-test using GraphPad Prism.

Transcriptomics analysis: Library preparation and sequencing were performed from a sample subset, sBPD (n=15) and BPD-PH (N=7), at the Penn State Health genomics core as previously described (21). Sample counts were uploaded to GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156028). The expression of the top differentially expressed gene (IL6) was validated by qPCR in a subset of samples (n=15).

Proteomics analysis: TAs containing 10 μg of protein were pooled and iTRAQ labeled according to published protocols (24) at the Penn State Health proteomics core. Peptides were identified and quantified using the Paragon Algorithm in ProteinPilotTM 4.5beta software (ABSciex) (25). Stringent Local false discovery rate (FDR) estimation was calculated from the Proteomics System Performance Evaluation Pipeline algorithm (26). Data analysis: For miRNA arrays, statistical analyses were performed with the R software using the Bioconductor limma package. For transcriptomics, filtered reads were aligned to the human reference genome (GRCh38) using HISAT2 (version 2.1.0) (27), and the resulting de-duplicated reads were summarized to each gene using HTSeq (28). Differential gene expression analysis was conducted with the edgeR package on R (29), after normalizing data with the TMM method (30). Heatmaps were generated with the

nonnegative matrix factorization package (31). For proteomics, data was analyzed using

the Scaffold Q+ for peptide and protein identifications, and probabilities were assigned by

the Protein Prophet algorithm (32). Channels were corrected in all samples according to

the i-Tracker algorithm (33). Normalization was performed iteratively on intensities, as

described in Statistical Analysis of Relative Labeled Mass Spectrometry Data from

Complex Samples Using ANOVA (34).

Pathway Analysis: The Ingenuity Pathway Analysis (IPA) software (QIAGEN) was used

to identify miRNA, mRNA and protein interaction networks, predicted target genes, and

molecular functions based on prediction scores (35). The core analysis functionality was

performed for direct and indirect relationships using the Ingenuity knowledge base.

Results

Patient demographics: TAs from 46 preterm infants needing mechanical ventilation

support were collected. Of there, 25 infants had sBPD without evidence of BPD-PH on

echocardiogram and 21 infants had clinical features characterized as sBPD with evidence

of BPD-PH on echocardiogram. A summary is shown in **Table 1**. No statistically

significant differences were found for measured variables including gestational age (GA)

at birth, birth weight, day of life at sample collection time, male sex, and racial/ethnicity

group. Birth delivery by C-section was higher in the sBPD group compared to BPD-PH.

Gestational age at the time of sample collection was significantly higher in the BPD-PH

7

group (Table 1).

miRNA analysis: A total of 1,059 miRNAs were expressed in TA samples from sBPD and BPD-PH (Figure 1). A list of miRNAs is shown in Supplementary Table 1, and a volcano plot is shown in Figure 2. After accounting for false discovery rate (FDR) < 0.05, the PCR array analysis revealed differential expression of 12 miRNAs with |FC| > 2 between the BPD-PH and sBPD samples (Table 2). Of these, 9 miRNAs (hsa-miR-29a, hsa-miR-542-3p, hsa-miR-624*, hsa-miR-3193, hsa-miR-3672, hsa-miR-3683, hsa-miR-501-3p, hsa-miR-101*, and hsa-miR-3128) had significantly higher expression in the BPD-PH group, compared to the sBPD group, whereas 3 miRNAs (hsa-miR-183*, hsa-miR-3131, and hsa-miR-1287) had significantly lower expression in BPD-PH vs. sBPD (Figure 3). Validation qPCR experiments in a select subset of samples confirmed upregulation of hsa-miR-29a, hsa-miR-542-3p, hsa-miR-624*, hsa-miR-501-3p and hsa-miR-101*, and downregulation of hsa-miR-183* in BPD-PH compared to sBPD samples (Figure 4).

Transcriptomic analysis: The RNA seq analysis in 22 samples (7 BPD-PH and 15 sBPD) detected expression of 64,253 total transcripts in TAs. Of these, 31,420 transcripts showed counts >10. A heatmap of gene expression is shown in **Figure 5**, and a volcano plot is shown in **Figure 6**. A total of 1,584 genes displayed differential expression between groups (|logFC| > 2, p<0.05), including 221 with higher expression in BPD-PH vs sBPD and 1,003 with lower expression in BPD-PH vs. sBPD (**Supplementary Table 2**). After correction for multiple comparisons, only 6 genes met the more stringent criteria for FDR<0.1 (IL6, RPL35P5, HSD3B7, RNA5SP215, OR2A1-AS1, and RNVU1-19) (**Table**

3). Of these, IL6 had the highest differential expression and lower FDR, thus we validated its expression using qPCR in a subset of samples (**Figure 7**).

Proteomics analysis: Proteomics analysis was conducted in a subset of TA samples derived from 7 BPD-PH and 5 sBPD infants. A total of 712 different proteins were identified using the proteinpilot software. Of these, 64 were significantly different between groups (Mann Whitney Test p <0.05) (FDR<0.2). Eight proteins had at least 2-fold change in the BPD-PH group compared to the sBPD group **(Table 4)**.

Pathway analysis: IPA analysis of differentially expressed miRNAs in BPD-PH vs. sBPD revealed significant associations with cell-to-cell signaling and interaction, cellular assembly and organization and cellular function and maintenance. The top physiological pathways associated with nervous system development and function, tissue development and cardiovascular system development and function. The top diseases and disorders associated were: cancer, organismal injury and abnormalities and gastrointestinal disease (Table 5). IPA analysis of differentially expressed transcripts showed involvement of cellular development, cellular growth and proliferation and cell death and survival. The top physiological pathways were associated with embryonic development, hematological system development and function and hematopoiesis, and the top disease and disorders associated were cardiovascular disease, developmental disorders, and hereditary disorder (Table 6). Similarly, IPA analysis of differentially expressed proteins identified molecular and cellular functions involving cellular compromise, protein synthesis, and cell death and survival. The top physiological pathway associated with

identified proteins was tissue morphology, visual system development and function and

organ morphology. The top diseases and disorders associated were inflammatory

response, cancer and organismal injury and abnormalities (Table 7). Finally, the

integrated pathway analysis of differentially expressed miRNAs, mRNAs and proteins

highlighted NFkB complex, VEGF, SERPINA1, as well as insulin, LDL, ERK1/2 and IL6

as the affected pathways in BPD-PH when compared to sBPD (Figure 8).

Discussion

Pulmonary hypertension associated with bronchopulmonary dysplasia is a multifactorial

disease with high morbidity and mortality (36). The mechanisms that differentiate the

pathophysiology of sBPD and BPD-PH development remain unknown, which limits our

ability to properly diagnose and treat infants (37). Using a multi-omic approach, our study

has identified a novel biomarker panel including 12 miRNAs, 6 transcripts, and 5 proteins

which distinguish infants with BPD-PH from those with sBPD who lack detectable PH on

echocardiogram. Target molecules identified via IPA are NFkB, VEGF, SERPINA1, IL6,

ERK12 and Insulin to name a few. Careful analysis of relevant individual markers

identified a recurring theme of angiogenesis, hyperoxic stress and vascular remodeling

as some of the key pathways that help endotype infants with severe lung disease with

and without PH.

Identifying disease endotypes using biomarkers will help not only identify underlying

mechanistic pathways, but also help clinically stratify high risk infants to help improve long

term outcomes. For this approach to have translational value, it is important to identify an affordable, minimally invasive, bedside point of care biomarker. Our study using TA

samples in preterm infants leverages a noninvasive easily obtained biofluids. This could

be a valuable tool to stratify at-risk infants and help clinical decision making.

Multi-omics approaches have been used to understand complex pulmonary disease such

as asthma, COPD, ARDS, IPF and PAH in order to develop personalized diagnostics and

treatments (38). While some studies have used Arginine metabolites to endotype

pulmonary arterial hypertension (39), we chose to conduct a non-targeted approach,

given that there is a complex array of prenatal and postnatal stressors associated with

BPD-PH that can result in arrested pulmonary vascular development. While antenatal and

perinatal factors including intrauterine growth restriction, preeclampsia, maternal

chorioamnionitis, and hypoxic and hyperoxic stress responses lead to abnormal

pulmonary vasculogenesis and alveolarization that have been associated with sBPD,

BPD-PH presents with vascular disease in its most severe form (40, 41). This suggests

that BPD-PH is a more severe spectrum of sBPD phenotype.

Our analysis revealed 9 miRNAs that were upregulated in BPD-PH when compared to

sBPD. Of particular interest, miRNA hsa-miR-29a, which is upregulated in BPD-PH, has

been previously linked with vascular disease. A publication by Chen et. al showed

upregulation of miRNA 29 by 16α-Hydroxyestrone resulting in BMPR2 associated

pulmonary hypertension both in human and animal models (42). Moreover, miRNA-29a

is also a well-studied biomarker for hypertrophic cardiomyopathy (43), and thus could

indicate myocardial stress as a result of elevated pulmonary pressure. Another study has noted microvesicle-secreted miR-29a/c significantly suppresses VEGF expression in gastric cancer, inhibiting vascular cell growth (44). Contradicting, in a pre-eclampsia model of human umbilical vein endothelial cells, knockdown of miRNA 29a/c-3p inhibited VEGF2 and FGF2 induced endothelial migration (45). Bhatt and colleagues demonstrated reduced expression of VEGF mRNA along with VEGF receptor in preterm infants with fatal lung disease (46), while Lassus and colleagues demonstrated lower VEGF in preterm infants with persistent severe lung disease when compared to those who recovered (16). Whether miRNA 29a is a biomarker of VEGF expression or cardiac stress in preterm infants with BPD-PH needs further exploration.

Another miRNA highly expressed in BPD-PH vs. sBPD was hsa-miR-542-3p. This miRNA has been shown to target BMP7 and regulate osteogenic transition of vascular smooth muscle cells in aging and hepatic fibrosis in rats (47, 48). Additionally, of the 3 down regulated miRNAs, hsa-miR-183 is typically expressed as a cluster miR-183-96-82 and packaged in exosomes expressed in high levels in cancer types including breast and prostate (49). This miRNA functions as an oncogene by targeting transcription factor EGR1 and promote tumor migration (50) and potentially inhibits NFKB-1 expression by directly targeting its 3'-untranslated region (51). Similarly, hsa-miR-101-5p has been studied to regulate cell proliferation through inhibition of RAP1A, which is involved in embryonic blood vessel formation (52). This miRNA has also been shown to inhibit growth, proliferation, and migration through targeting Sex-determining Region Y- Box 2

(SOX2) (53). Overall, our miRNA analysis revealed multiple potential key players of the

mechanisms involved in BPH-PH progression.

While our transcriptomic analysis identified multiple pseudogenes, and non-coding RNAs

as the top differentially expressed transcripts between BPD-PH and sBPD, it also

revealed IL6 as a highly expressed gene in TAs from infants with BPD-PH. Previously, a

multicenter study identified IL6 as a clinical marker to predict severe phenotype in

pediatric pulmonary arterial hypertension (54). This cytokine has been found to modulate

expression of BMPR2 (55) similar to miRNA 29a which plays a role in vascular remodeling

(56). In addition, IL6 is shown to be an important clinical marker for clinical phenotype

and survival in patients with pulmonary hypertension. Another differentially expressed

gene identified was HSD3B7 which has been shown to regulate endometrial activity in

women with polycystic ovarian syndrome (57) who's novel mutation is found to be

associated with neonatal cholestasis (58).

Finally, our proteomic analysis revealed Galectin 3 binding protein precursor gene as the

most differentially expressed protein. Galectin is an important mediator of VEGF and

bFGF mediated angiogenic response which has been shown to be reduced in the

presence of Galectin 3 inhibitors (59, 60). Another protein of interest was Surfactant

protein B, as gene polymorphisms of SFPB have shown to be associated with BPD and

13

newborn respiratory distress syndrome (61, 62).

The IPA analysis conducted separately for the differentially expressed miRNAs, mRNAs and proteins showed cellular movement, cellular development and cell-to cell signaling as the common top molecular functions suggesting pathways regulating growth and organ development. The analysis revealed that the top physiological systems were nervous system development and function, embryonic development and tissue morphology. Some of the strengths of our study are our non-biased approach to identify biomarkers to endotype preterm infants with sBPD vs. BPD-PH. Using a multi-omic approach helped us identify coding and non-coding, as well as transcriptional, and post transcriptional markers. We used bioinformatic tools to identify key pathways and mechanisms converging and comparing the miRNAs, mRNA and proteomic data. Given the complex pathophysiology of sBPD and BPD-PH, our study combining biological fluids with a multiomic approach identified predicted targets that have been culminated by various pathways resulting in sBPD and BPD-PH phenotypes. To ensure inter reporting bias, all echocardiograms were reviewed by a single pediatric cardiologist. We excluded ELGANs with hemodynamically significant intracardiac shunt in the study to eliminate confounding factors resulting from pulmonary over circulation or sheer stress on pulmonary vasculature.

Despite our findings, this study is not without limitations. As a pilot study, the size of the study cohort leaves opportunity for a larger follow up study. However, while a study size of 46 preterm infants seems like a smaller cohort, it is very challenging to recruit and conduct sample analysis from ELGANs especially those who are invasively ventilated, since the clinical preference is to noninvasively ventilate which limits our access to

tracheal aspirate samples. Echocardiograms were used as the diagnostic tool, which

could be criticized as it lacks the sensitivity and specificity of the gold standard cardiac

catheterization; however, we point out the limitation of reliance on invasive cardiac

catheterization in extreme preterm infants which is a population less likely to undergo

cardiac catheterization. There have been multiple studies validating specific

echocardiogram parameters with high correlation with cardiac catheterization (63-65).

Identifying pathological biomarkers would help increase the sensitivity and specificity of

non-invasive tools such as echocardiograms which measure indirect evidence of

pulmonary vascular resistance.

In conclusion, there is a significant overlap in the pathophysiology of sBPD and BPD-PH

along with their clinical signs and symptoms. Our study evaluated and identified specific

multi-omic markers in tracheal aspirate of ELGANS that aid in specific endotyping of the

complex disease of pulmonary vascular disease associated with BPD in these infants.

We report specific miRNAs, transcripts, and proteins that could potentially serve as

markers of angiogenesis and inflammatory biomarkers of pulmonary vascular disease

15

pathology in preterm infants with BPD.

Acknowledgements

The authors would like to thank the Penn State Health Proteomics Core facility staff, and its director Dr. Bruce Stanley for proteomic analysis. We also thank Diane Kitch for data coordination and IRB approval assistance, as well as Debra Spear and Susan DiAngelo for sample collection and processing, and Mathew Steadman and Dr. Chongben Zhang from the University of North Carolina at Chapel Hill Biobehavioral Core facility for sample storage and processing.

References

- 1. Baraldi E, Filippone M. Chronic lung disease after premature birth. *N Engl J Med* 2007; 357: 1946-1955.
- Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins JW, Jr.
 Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. *Pediatrics* 1985; 75: 80-84.
- 3. Ali Z, Schmidt P, Dodd J, Jeppesen DL. Predictors of bronchopulmonary dysplasia and pulmonary hypertension in newborn children. *Dan Med J* 2013; 60: A4688.
- 4. An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, Kim HS, Choi JH, Noh CI, Yun YS. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. *Korean Circ J* 2010; 40: 131-136.
- Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. *Curr Opin Pediatr* 2013; 25: 329-337.
- 6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001; 163: 1723-1729.
- 7. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med 2019; 200: 751-759.

- 8. Baker CD, Abman SH, Mourani PM. Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia. *Pediatr Allergy Immunol Pulmonol* 2014; 27: 8-16.
- Berkelhamer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 124-131.
- Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. *Pediatrics* 2012; 129: e682-689.
- 11. Akangire G, Manimtim W, Nyp MF, Noel-MacDonnell J, Kays AN, Truog WE, Taylor JB. Clinical Outcomes among Diagnostic Subgroups of Infants with Severe Bronchopulmonary Dysplasia through 2 Years of Age. Am J Perinatol 2018; 35: 1376-1387.
- 12. Collaco JM, Romer LH, Stuart BD, Coulson JD, Everett AD, Lawson EE, Brenner JI, Brown AT, Nies MK, Sekar P, Nogee LM, McGrath-Morrow SA. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. *Pediatr Pulmonol* 2012; 47: 1042-1053.
- 13. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, Truog WE, McGrath-Morrow SA, Moore PE, Rhein LM, Kirpalani H, Zhang H, Gratny LL, Lynch SK, Curtiss J, Stonestreet BS, McKinney RL, Dysart KC, Gien J, Baker CD, Donohue PK, Austin E, Fike C, Nelin LD, Bronchopulmonary Dysplasia C. Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. *J Pediatr* 2017; 181: 12-28 e11.

- 14. Wu KY, Jensen EA, White AM, Wang Y, Biko DM, Nilan K, Fraga MV, Mercer-Rosa L, Zhang H, Kirpalani H. Characterization of Disease Phenotype in Very Preterm Infants with Severe Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2020; 201: 1398-1406.
- 15. Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". *Am J Respir Crit*Care Med 2001; 164: 1755-1756.
- 16. Lassus P, Turanlahti M, Heikkila P, Andersson LC, Nupponen I, Sarnesto A, Andersson S. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001; 164: 1981-1987.
- 17. Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. *Am J Physiol Lung Cell Mol Physiol* 2012; 302: L36-46.
- 18. Kim DH, Kim HS. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension. *Neonatology* 2014; 106: 55-61.
- 19. Vera KB, Moore D, Flack E, Liske M, Summar M. Significant Differences in Markers of Oxidant Injury between Idiopathic and Bronchopulmonary-Dysplasia-Associated Pulmonary Hypertension in Children. *Pulm Med* 2012; 2012: 301475.

- 20. Yum SK, Kim MS, Kwun Y, Moon CJ, Youn YA, Sung IK. Impact of histologic chorioamnionitis on pulmonary hypertension and respiratory outcomes in preterm infants. *Pulm Circ* 2018; 8: 2045894018760166.
- 21. Oji-Mmuo CN, Siddaiah R, Montes DT, Pham MA, Spear D, Donnelly A, Fuentes N, Imamura-Kawasawa Y, Howrylak JA, Thomas NJ, Silveyra P. Tracheal aspirate transcriptomic and miRNA signatures of extreme premature birth with bronchopulmonary dysplasia. *J Perinatol* 2021; 41: 551-561.
- 22. Schwarzenbach H, da Silva AM, Calin G, Pantel K. Data Normalization Strategies for MicroRNA Quantification. *Clin Chem* 2015; 61: 1333-1342.
- 23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; 25: 402-408.
- 24. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, clCAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. *J Proteome Res* 2006; 5: 651-658.
- 25. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. *Mol Cell Proteomics* 2007; 6: 1638-1655.

- 26. Tang WH, Shilov IV, Seymour SL. Nonlinear fitting method for determining local false discovery rates from decoy database searches. *J Proteome Res* 2008; 7: 3661-3667.
- 27. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol* 2019; 37: 907-915.
- 28. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics* 2015; 31: 166-169.
- 29. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010; 26: 139-140.
- 30. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol* 2010; 11: R25.
- 31. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization.

 Bmc Bioinformatics 2010; 11: 367.
- 32. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. *Anal Chem* 2003; 75: 4646-4658.
- 33. Shadforth IP, Dunkley TP, Lilley KS, Bessant C. i-Tracker: for quantitative proteomics using iTRAQ. *BMC Genomics* 2005; 6: 145.

- 34. Oberg AL, Mahoney DW, Eckel-Passow JE, Malone CJ, Wolfinger RD, Hill EG, Cooper LT, Onuma OK, Spiro C, Therneau TM, Bergen HR, 3rd. Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. *J Proteome Res* 2008; 7: 225-233.
- 35. Fuentes N, Roy A, Mishra V, Cabello N, Silveyra P. Sex-specific microRNA expression networks in an acute mouse model of ozone-induced lung inflammation. *Biol Sex Differ* 2018; 9: 18.
- 36. Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M, (EPPVDN) EPPVDN. Pulmonary hypertension in bronchopulmonary dysplasia.

 Pediatr Res 2021; 89: 446-455.
- 37. Levy PT, Levin J, Leeman KT, Mullen MP, Hansmann G, Kourembanas S.

 Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2022: 101351.
- 38. Kan M, Shumyatcher M, Himes BE. Using omics approaches to understand pulmonary diseases. *Respir Res* 2017; 18: 149.
- 39. Kao CC, Wedes SH, Hsu JW, Bohren KM, Comhair SA, Jahoor F, Erzurum SC.

 Arginine metabolic endotypes in pulmonary arterial hypertension. *Pulm Circ*2015; 5: 124-134.
- 40. Torchin H, Ancel PY, Goffinet F, Hascoet JM, Truffert P, Tran D, Lebeaux C, Jarreau PH. Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study. *Pediatrics* 2016; 137: e20152163.

- 41. Mourani PM, Abman SH. Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia. *Clin Perinatol* 2015; 42: 839-855.
- 42. Chen X, Talati M, Fessel JP, Hemnes AR, Gladson S, French J, Shay S, Trammell A, Phillips JA, Hamid R, Cogan JD, Dawson EP, Womble KE, Hedges LK, Martinez EG, Wheeler LA, Loyd JE, Majka SJ, West J, Austin ED. Estrogen Metabolite 16alpha-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. *Circulation* 2016; 133: 82-97.
- 43. Dai Y, Dai D, Mehta JL. MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker. *J Am Coll Cardiol* 2014; 64: 2181.
- 44. Zhang H, Bai M, Deng T, Liu R, Wang X, Qu Y, Duan J, Zhang L, Ning T, Ge S, Li H, Zhou L, Liu Y, Huang D, Ying G, Ba Y. Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. *Cancer Lett* 2016; 375: 331-339.
- 45. Zhou C, Zou QY, Li H, Wang RF, Liu AX, Magness RR, Zheng J. Preeclampsia

 Downregulates MicroRNAs in Fetal Endothelial Cells: Roles of miR-29a/c-3p in

 Endothelial Function. *J Clin Endocrinol Metab* 2017; 102: 3470-3479.
- 46. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM.

 Disrupted pulmonary vasculature and decreased vascular endothelial growth

- factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia.

 Am J Respir Crit Care Med 2001; 164: 1971-1980.
- 47. Liu H, Wang H, Yang S, Qian D. Downregulation of miR-542-3p promotes osteogenic transition of vascular smooth muscle cells in the aging rat by targeting BMP7. *Hum Genomics* 2019; 13: 67.
- 48. Ji F, Wang K, Zhang Y, Mao XL, Huang Q, Wang J, Ye L, Li Y. MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7. *J Cell Biochem* 2019; 120: 4573-4581.
- 49. Mihelich BL, Dambal S, Lin S, Nonn L. miR-182, of the miR-183 cluster family, is packaged in exosomes and is detected in human exosomes from serum, breast cells and prostate cells. *Oncol Lett* 2016; 12: 1197-1203.
- 50. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010; 70: 9570-9580.
- 51. Sha F, Wu S, Zhang H, Guo X. miR-183 potentially inhibits NF-kappaB1 expression by directly targeting its 3'-untranslated region. *Acta Biochim Biophys Sin* (Shanghai) 2014; 46: 991-996.
- 52. Shibayama Y, Kubo Y, Nakagawa T, Iseki K. MicroRNA-101-5p Suppresses the Expression of the Ras-Related Protein RAP1A. *Biol Pharm Bull* 2019; 42: 1332-1336.

- 53. Wang J, Zeng H, Li H, Chen T, Wang L, Zhang K, Chen J, Wang R, Li Q, Wang S. MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2. Cell Physiol Biochem 2017; 43: 717-732.
- 54. Chen JY, Griffiths M, Yang J, Nies MK, Damico RL, Simpson CE, Vaidya RD, Brandal S, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. *J Pediatr* 2020; 223: 164-169 e161.
- 55. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104: 1184-1191.
- 56. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y.
 Downregulation of type II bone morphogenetic protein receptor in hypoxic
 pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 290: L450-458.
- 57. Plaza-Parrochia F, Poblete C, Gabler F, Carvajal R, Romero C, Valladares L, Vega M. Expression of steroid sulfated transporters and 3beta-HSD activity in endometrium of women having polycystic ovary syndrome. *Steroids* 2015; 104: 189-195.

- 58. Huang HY, Zhou H, Wang H, Chen YX, Fang F. Novel Mutations in the 3beta-hydroxy-5-C27-steroid Dehydrogenase Gene (HSD3B7) in a Patient with Neonatal Cholestasis. *Chin Med J (Engl)* 2016; 129: 98-100.
- 59. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A.
 Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J
 Pathol 2000; 156: 899-909.
- 60. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGFand bFGF-mediated angiogenic response. *J Exp Med* 2010; 207: 1981-1993.
- 61. Pavlovic J, Papagaroufalis C, Xanthou M, Liu W, Fan R, Thomas NJ, Apostolidou I, Papathoma E, Megaloyianni E, DiAngelo S, Floros J. Genetic variants of surfactant proteins A, B, C, and D in bronchopulmonary dysplasia. *Dis Markers* 2006; 22: 277-291.
- 62. Cai BH, Chang LW, Li WB, Liu W, Wang XJ, Mo LX, Zhao LX, Xu HT, Yang H.

 Association of surfactant protein B gene polymorphisms (C/A-18, C/T1580, intron 4 and A/G9306) and haplotypes with bronchopulmonary dysplasia in chinese han population. *J Huazhong Univ Sci Technolog Med Sci* 2013; 33: 323-328.
- 63. Nawaytou H, Steurer MA, Zhao Y, Guslits E, Teitel D, Fineman JR, Keller RL.
 Clinical Utility of Echocardiography in Former Preterm Infants with
 Bronchopulmonary Dysplasia. J Am Soc Echocardiogr 2020; 33: 378-388 e371.
- 64. Kuppahally SS, Michaels AD, Tandar A, Gilbert EM, Litwin SE, Bader FM. Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right

heart catheterizations in end-stage heart failure patients awaiting transplantation? *Am J Cardiol* 2010; 106: 1657-1662.

65. Patel MD, Breatnach CR, James AT, Choudhry S, McNamara PJ, Jain A, Franklin O, Hamvas A, Mertens L, Singh GK, El-Khuffash A, Levy PT. Echocardiographic Assessment of Right Ventricular Afterload in Preterm Infants: Maturational Patterns of Pulmonary Artery Acceleration Time Over the First Year of Age and Implications for Pulmonary Hypertension. *J Am Soc Echocardiogr* 2019; 32: 884-894 e884.

Tables

Table 1 Patient demographics at study enrollment

Ob a manufaction	sBPD	BPD+PH	p-Value	
Characteristic	(n = 25)	(n = 21)		
Gestational age (GA) at birth,	25.88 ± 1.53	25.41 ± 1.82	0.345	
weeks (mean ± SD)	25.00 ± 1.55	20.41 ± 1.02	0.040	
GA at sample collection, weeks	36.15 ± 10.88	44.06 ± 14.73	0.042	
(mean ± SD)	00.10 = 10.00	11.00 = 11.110	0.012	
Birth weight, grams (mean ±	747 ± 206	647 ± 208	0.112	
SD)		011 2200	01112	
Male sex, % (n)	56 (14)	62 (13)	0.345	
Fractional inspired oxygen				
during sample collection (mean	0.37 ± 0.13	0.35 ± 0.10	0.572	
± SD)				
Delivered via C-section, % (n)	88 (22)	43 (9)	0.002	
Racial/ethnic group, % (n)				
Non-Hispanic White	52 (13)	57 (12)	0.845	
Non-Hispanic Black	4 (1)	5 (1)	1.0	
Hispanic	24 (6)	14 (3)	0.477	
Asian	12 (3)	0 (0)	0.240	
More than one race	8 (2)	24 (5)	0.220	

Table 2. Differentially expressed miRNAs in BPD-PH vs. sBPD tracheal aspirates

miRNA ID	Log (FC)	Average Expression	Adjusted p-value
hsa-miR-542-3p	4.487	4.098	0.022
hsa-miR-624*	3.959	3.510	0.024
hsa-miR-501-3p	0.817	1.105	0.027
hsa-miR-183*	-2.135	2.509	0.031
hsa-miR-101*	0.518	0.843	0.037
hsa-miR-3131	-0.476	0.574	0.040
hsa-miR-3683	1.037	1.290	0.040
hsa-miR-3193	2.307	2.372	0.042
hsa-miR-29a	5.077	6.423	0.042
hsa-miR-3672	1.207	0.644	0.044
hsa-miR-3128	0.369	0.282	0.046
hsa-miR-1287	-3.686	3.155	0.046

Table 3 Differentially expressed transcripts in tracheal aspirates of BPD-PH vs. sBPD patients

Gene ID	Gene name	Log (FC)	p-value	FDR
IL6	Interleukin 6	4.372	4.777	5.55E-02
RPL35P5	Ribosomal Protein L35 Pseudogene 5	3.002	5.788	5.55E-02
	Hydroxy-Delta-5-Steroid			
HSD3B7	Dehydrogenase, 3 Beta- and Steroid			
	Delta-Isomerase 7	3.674	4.896	5.99E-02
RNA5SP215	RNA, 5S Ribosomal Pseudogene 215	3.362	5.230	5.99E-02
OR2A1-AS1	OR2A1 Antisense RNA 1	-5.147	5.654	5.99E-02
RNVU1-19	RNA, Variant U1 Small Nuclear 19	3.397	5.062	5.99E-02

Table 4. Differentially expressed proteins in tracheal aspirates of BPD-PH vs. sBPD patients

Proteins	Log (FC)	Mann-Whitney Test	Adjusted p-value
calcyphosin isoform a	-2.24	0.021	0.041
alpha-1-antitrypsin precursor	-2.26	0.005	0.055
keratin, type II cytoskeletal 5	-2.42	0.034	0.094
pulmonary surfactant-associated		0.009	0.110
protein B precursor	-3.11		
galectin-3-binding protein precursor	-4.04	0.020	0.114

Table 5: IPA pathway associated with differentially expressed miRNA in BPD-PH versus sBPD

Molecular and Cellular Functions	P-Value Range	Number of
		Molecules
Cell-To-cell Signaling and Interaction	1.27E-03 – 5.08E-04	2
Cellular Assembly and Organization	2.03E-03 - 5.08E-04	2
Cellular Function and Maintenance	1.54E-02 – 5.08E-04	2
Cellular Development	4.95E-02 – 8.44E-04	4
Cellular Growth and Proliferation	4.95E-02 – 8.44E-04	4
Physiological System Development and Function		
Nervous System Development and Function	8.87E-03 – 5.08E-04	2
Tissue Development	1.54E-03 – 5.08E-04	3
Cardiovascular System Development and Function	1.27E-03 – 1.27E-03	1
Connective Tissue Development and Function	4.56E-03 – 1.27E-03	2
Hematological System Development and Function	1.54E-03 – 1.27E-03	1
Diseases and disorders		
Cancer	4.47E-02 – 1.56E-04	5
Organismal Injury and Abnormalities	4.47E-02 – 1.56E-04	6
Gastrointestinal Disease	4.20E-02 – 3.19E-04	5
Respiratory Disease	3.19E-04 – 3.19E-04	2
Tumor Morphology	2.54E-03 – 1.02E-03	1

Table 6: IPA pathway associated with differentially expressed mRNA in BPD-PH versus sBPD

Molecular and Cellular Functions	P-Value Range	Number of
		Molecules
Cellular Development	6.29E-03 - 6.69E-06	3
Cellular Growth and Proliferation	6.29E-03 - 6.69E-06	3
Cell Death and Survival	6.04E-03 – 4.12E-05	3
Cell Morphology	5.79E-03 – 6.46E-05	2
Cell-To-Cell Signaling and Interaction	5.54E-03 – 2.52E-04	1
Physiological System Development and Function		
Embryonic Development	6.29E-03 - 6.69E-06	3
Hematological System Development and Function	6.29E-03 – 6.69E-06	3
Hematopoiesis	6.29E-03 – 6.69E-06	3
Lymphoid Tissue structure and Development	6.29E-03 – 6.69E-06	3
Organ Development	6.29E-03 - 6.69E-06	3
Diseases and disorders		
Cardiovascular Disease	5.28E-03 – 1.22E-05	3
Developmental Disorder	3.53E-03 – 1.22E-05	2
Hereditary Disorder	2.52E-03 – 1.22E-05	2
Neurological Disorder	5.79E-03 – 1.22E-05	2
Organismal Injury and Abnormalities	6.29E-03 – 1.22E-05	5

Table 7: IPA pathway associated with differentially expressed proteomics in BPD-PH versus sBPD

Molecular and Cellular Functions	P-Value Range	Number of
		Molecules
Cellular Compromise	2.41E-02 - 5.94E-10	8
Protein Synthesis	2.18E-02 – 2.71E-06	7
Cell death and Survival	2.10E-02 - 1.82E-05	9
Cell Morphology	1.63E-02 – 2.70E-05	8
Cellular Movement	2.32E-03 – 2.70E-05	7
Physiological System Development and		
Function		
Tissue Morphology	1.76E-02 - 6.03E-06	6
Visual System Development and Function	6.04E-07 - 6.04E-07	3
Organ Morphology	2.36E-02 - 9.02E-06	5
Organismal Development	2.36E-02 - 9.02E-06	7
Reproductive System Development and Function	2.04E-02 - 9.02E-06	2
Diseases and disorders		
Inflammatory Response	2.32E-02 - 5.94E-10	10
Cancer	2.29E-02 - 6.03E-07	12
Organismal Injury and Abnormalities	2.45E-02 - 6.03E-07	12
Reproductive System Disease	2.43E-02 - 6.03E-07	8
Developmental Disorder	1.99E-02 – 7.85E-06	9

Figures

Figure 1.




Figure 1. MiRNA expression in tracheal aspirates. Heatmap of expression of 1048 miRNAs in tracheal aspirates from infants with sBPD (n=25) and BPD-PH (n=21) (normalized by global mean), obtained by PCR arrays. Heatmap generated in R using the NMF package.

Figure 2.




Figure 2. Volcano plot. Negative of false discovery rate vs. log of fold change of miRNAs between BPD-PH and sBPD groups. Vertical lines show |FC|=2 and horizontal line indicates FDR=0.05.

Figure 3.




Figure 3. Top differentially expressed miRNAs. Y axes indicate relative expression values after global normalization. Graphs and calculations were done in R using the limma package.

Figure 4.




Figure 4. miRNA validation. Validation of miRNA expression by Real Time PCR. Y axes indicate relative expression values after normalization to miR-16, and a BPD-PH calibration sample using the $2^{-\Delta\Delta CT}$ method (22, 23). Significant differences were determined by t-test using the GraphPad software (* p < 0.05)

Figure 5.




Figure 5. Transcriptomic analysis of tracheal aspirates. Heatmap of RNAseq counts (>10) for transcripts in TAs samples from BPD-PH (n=7) and sBPD (n=15) infants.

Figure 6.




Figure 6. Volcano plot of mRNA transcripts. Negative log of false discovery rate vs. log of fold change of mRNAs between BPD-PH and sBPD groups. Horizontal line indicates FDR=0.05.

Figure 7.




Figure 7. Interleukin-6 mRNA expression in tracheal aspirates. Validation of IL6 expression using Real-Time PCR shows increased expression in BPD-PH (n=8) samples compared to sBPD (n=7) (p<0.05)

Figure 8.




Figure 8. IPA pathways. Ingenuity pathway analysis of the differentially expressed miRNAs, proteins, and mRNAs in TAs of sBPD and BPD-PH